公开(公告)号：US11479605B2

公开(公告)日：2022-10-25

申请号：US16784778

申请日：2020-02-07

Applicant: Nykode Therapeutics ASA

Inventor： Pier Adelchi Ruffini ,  Bjarne Bogen ,  Agnete Brunsvik Fredriksen

IPC: C07K16/28 ,  A61K39/00 ,  C07K16/44 ,  A61K39/145 ,  A61K39/12

Abstract: The present invention relates to novel recombinant fusion proteins, such as human antibody-based molecules called Vaccibodies, which are able to trigger both a T cell- and B cell immune response. The present invention also relates to a method of treating a cancer or an infectious disease by means of these specific fusion proteins.

公开(公告)号：US20240132596A1

公开(公告)日：2024-04-25

申请号：US18469961

申请日：2023-09-18

Applicant: UNIVERSITY OF OSLO ,  Nykode Therapeutics ASA

Inventor： Gunnveig Grodeland ,  Bjarne Bogen ,  Agnete B. Fredriksen

IPC: C07K16/28 ,  A61K39/00 ,  A61K39/12 ,  A61K39/39 ,  C07K16/34 ,  C07K16/46

CPC classification number: C07K16/2833 ,  A61K39/00 ,  A61K39/12 ,  A61K39/39 ,  C07K16/34 ,  C07K16/46 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/622

Abstract: The present invention relates to an immunoglobulin derived single-chain fragment variable (scFv) that broadly binds HLA II molecules and uses thereof. In particular, targeting of an antigen to antigen presenting cells with the HLAII-specific targeting unit provided herein find use in enhancing immune responses after vaccination.

公开(公告)号：US20240228624A9

公开(公告)日：2024-07-11

申请号：US18469961

申请日：2023-09-19

Applicant: UNIVERSITY OF OSLO ,  Nykode Therapeutics ASA

Inventor： Gunnveig Grodeland ,  Bjarne Bogen ,  Agnete B. Fredriksen

IPC: C07K16/28 ,  A61K39/00 ,  A61K39/12 ,  A61K39/39 ,  C07K16/34 ,  C07K16/46

CPC classification number: C07K16/2833 ,  A61K39/00 ,  A61K39/12 ,  A61K39/39 ,  C07K16/34 ,  C07K16/46 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/622

Abstract: The present invention relates to an immunoglobulin derived single-chain fragment variable (scFv) that broadly binds HLA II molecules and uses thereof. In particular, targeting of an antigen to antigen presenting cells with the HLAII-specific targeting unit provided herein find use in enhancing immune responses after vaccination.

公开(公告)号：US20230065226A1

公开(公告)日：2023-03-02

申请号：US17934348

申请日：2022-09-22

Applicant: Nykode Therapeutics ASA

Inventor： Pier Adelchi Ruffini ,  Bjarne Bogen ,  Agnete Brunsvik Fredriksen

IPC: C07K16/28 ,  A61K39/00 ,  C07K16/44 ,  A61K39/145 ,  A61K39/12

Abstract: The present invention relates to novel recombinant fusion proteins, such as human antibody-based molecules called Vaccibodies, which are able to trigger both a T cell- and B cell immune response. The present invention also relates to a method of treating a cancer or an infectious disease by means of these specific fusion proteins.